Future of Respiratory Biologics

At the conclusion of this session, the participant should be able to:

1. Describe the role of epithelial cell–derived cytokines (alarmins) such as TSLP, IL-33, and IL-25 in the pathogenesis of asthma and other respiratory diseases.
2. Evaluate emerging biologic therapies targeting novel inflammatory pathways—including anti-TSLP, anti-IL-33/ST2, and anti-GM-CSF—and their potential indications in asthma, COPD, and nasal polyposis.
3. Discuss the clinical relevance and therapeutic potential of targeting non–type 2 inflammatory pathways, including IL-6, IL-1β, and OX40/OX40L, in severe and treatment-resistant respiratory conditions.

ACCREDITATION

The Pennsylvania Osteopathic Medical Association (POMA) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. POMA designates this activity for a maximum of 1 Category 1-A AOA CME credits and will report CME and specialty credits to the AOA commensurate with the extent of the physician’s participation in this activity.

GRIEVANCE POLICY STATEMENT

It is the policy of the POMA that any physician dissatisfied with the CME program will be issued a refund upon request, and no CME credits will be reported to the AOA.  Complaints on Evaluation Forms are also taken into consideration when planning future CME programs and may lead to changes in the format or content."  If you have any questions or concerns about this educational experience, you may call the POMA office at (717) 939-9318 or send an email message to cme@poma.org.  All questions or concerns will be addressed promptly.